Medipharm Labs Corp

MediPharm Labs Corp has a market cap of CAD 38.24 million and a price-to-book ratio of 1.07, indicating a valuation in line with tangible book value. The company holds CAD 10.81 million in cash and equivalents, with total liabilities of CAD 9.93 million, yielding a current ratio of 2.77, suggesting strong short-term liquidity. However, negative operating cash flow of CAD -5.67 million and free cash flow of CAD -6.71 million highlight ongoing cash burn. Profitability metrics show a return on equity of -23.08% and return on assets of -18.07%, both significantly below the industry median for pharmaceutical firms, which typically exceed 10% ROE and 8% ROA. Gross profit of CAD 12.19 million on CAD 45.12 million in revenue yields a 27% margin, but operating losses of CAD 8.44 million and net losses of CAD 8.27 million indicate structural inefficiencies. The company’s revenue is concentrated in domestic and international cannabis markets, with no disclosed segment breakdown, but international subsidiaries in Germany and Australia suggest geographic diversification. No major revenue concentration risks are flagged in the input data. Outlook data is not provided in the input, but historical revenue growth is not specified. Analysts rate the stock as a single "Hold," with no buy or sell recommendations, and the most recent actual EPS of -0.02 CAD versus a mean estimate of -0.01 CAD suggests earnings are tracking below expectations. Risk assessment flags low liquidity and dilution risk, with no immediate filing-based red flags. The company has minimal long-term debt (CAD 201,000) and no dilution pressure from shares outstanding, with basic and diluted shares equal at 424.86 million. Recent events include no disclosed filings or transcripts in the input data, but the company’s ongoing losses and negative cash flows suggest operational challenges that may require capital raises or cost restructuring in the near term.